Recent antimalarial drug discovery has been a race to produce new medicines that
overcome emerging drug resistance, whilst considering safety and improving dosing …

Leishmaniasis (visceral and cutaneous), Chagas disease and human African
trypanosomiasis cause substantial death and morbidity, particularly in low-and middle …

Introduction: Spirooxindole, a unique and versatile scaffold, has been widely studied in
some fields such as pharmaceutical chemistry and synthetic chemistry. Especially in the …

Neglected tropical diseases (NTDs) as termed by WHO include twenty different infectious
diseases that are caused by bacteria, viruses, and parasites. Among these NTDs, Chagas …

Visceral leishmaniasis is responsible for up to 30,000 deaths every year. Current treatments
have shortcomings that include toxicity and variable efficacy across endemic regions …

In September 2022, the Drug Discovery Unit at the University of Dundee, UK, organised an
international meeting at the Wellcome Collection in London to explore the current clinical …

Millions who live in Latin America and sub-Saharan Africa are at risk of trypanosomatid
infections, which cause Chagas disease and human African trypanosomiasis (HAT) …

Visceral leishmaniasis (VL) is a parasitic disease endemic across multiple regions of the
world and is fatal if untreated. Current therapies are unsuitable, and there is an urgent need …

Leishmaniasis is a vector-borne parasitic disease caused by Leishmania species. The
disease affects humans and animals, particularly dogs, provoking cutaneous …

Chagas disease is the most important protozoan infection in the Americas, and constitutes a
significant public health concern throughout the world. Development of new medications …